N-Methyl-D-Aspartate Receptor Antagonists in Major Depression
Summary
Major depressive disorder remains a leading cause of disability worldwide, with a substantial proportion of patients experiencing inadequate response to conventional monoaminergic therapies. Growing evidence implicates glutamatergic dysfunction and impaired synaptic plasticity in its pathophysiology, directing attention to N-Methyl-D-Aspartate (NMDA) receptor antagonism as a novel therapeutic strategy. Ketamine, a non-competitive NMDA receptor blocker, has revolutionised the field by demonstrating rapid and robust antidepressant effects at subanaesthetic doses, characterised by onset of symptom relief within hours and modulation of circuit connectivity in prefrontal and limbic regions. Its mechanism is thought to involve preferential blockade of NMDA receptors on GABAergic interneurons, disinhibition of glutamate release, enhanced AMPA receptor throughput, and downstream upregulation of brain-derived neurotrophic factor (BDNF) and mammalian target of rapamycin (mTOR) signalling pathways, culminating in renewed synaptogenesis and network plasticity. Despite these advances, transient efficacy, psychotomimetic side-effects and logistical challenges have spurred development of next-generation agents. These include esketamine nasal spray, NR2B-selective antagonists, glycine-site modulators, and compounds combining NMDA antagonism with sigma or opioid receptor activity such as dextromethorphan–bupropion formulations. Adjunctive use of memantine and amantadine has been explored to augment standard antidepressants, albeit with mixed outcomes. Ongoing preclinical and clinical research aims to refine targeting of NMDA subunits, identify predictive biomarkers of response, and integrate glutamate-modulating strategies into personalised care frameworks, offering promise for rapid-onset, sustained relief in treatment-resistant depression.
Research from Nature Portfolio
No recent Nature Portfolio content available.
N-Methyl-D-Aspartate Receptor Antagonists in Major Depression publication trend
The graph below shows the total number of articles in n-methyl-d-aspartate receptor antagonists in major depression across all publications each year (not limited to Nature Index journals).
Technical terms
N-Methyl-D-Aspartate (NMDA) receptor: A subtype of ionotropic glutamate receptor that mediates calcium and sodium influx, essential for synaptic plasticity and excitatory neurotransmission.
GABAergic interneuron: An inhibitory neuron releasing gamma-aminobutyric acid (GABA) that modulates excitatory circuits and network synchronisation.
AMPA receptor: A fast-acting ionotropic glutamate receptor that mediates the majority of excitatory synaptic transmission in the brain.
Brain-derived neurotrophic factor (BDNF): A neurotrophin that supports neuronal survival, growth and synaptic plasticity.
Mammalian target of rapamycin (mTOR): A kinase that regulates protein synthesis and synaptic growth in response to cellular signals.
Synaptogenesis: The formation of new synaptic connections between neurons, critical for learning and plasticity.
References
- Amantadine in Treatment of Dysthymia—The Pilot Case Series Study. Pharmaceuticals (2023).
- Possible Antidepressant Effects of Memantine—Systematic Review with a Case Study. Pharmaceuticals (2021).
- NMDA Receptor Antagonists for Treatment of Depression. Pharmaceuticals (2013).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.